Compare TALKW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALKW | SCLXW |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | 598 | 34 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | TALKW | SCLXW |
|---|---|---|
| Price | $0.00 | $0.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 166.5K | 2.9K |
| Earning Date | 02-20-2025 | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $181,291,000.00 | $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | 22.02 |
| 52 Week Low | $0.00 | $0.05 |
| 52 Week High | $0.10 | $0.64 |
| Indicator | TALKW | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 53.30 |
| Support Level | N/A | $0.11 |
| Resistance Level | $0.01 | $0.18 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 76.94 |
Talkspace Inc is a virtual behavioral healthcare company offering its members convenient and affordable access to a fully-credentialed network of qualified providers across a wide and growing spectrum of care through virtual psychotherapy and psychiatry. It is a single destination for comprehensive mental health care, including therapy for individuals, couples, and teens, as well as psychiatric treatment and medication management (18+), and self-guided tools and resources. The company's customers include Health insurance plans from commercial and government institutions, and employee assistance programs, Direct-to-Enterprise, and Individual subscribers. The company operates as a single segment.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.